Quale sarebbe il prezzo per Altamira Therapeutics Ltd. (CYTO)

Il prezzo per Altamira Therapeutics Ltd. (CYTO) è $0.3

Qual è la capitalizzazione di mercato per Altamira Therapeutics Ltd. (CYTO)

La capitalizzazione di mercato per Altamira Therapeutics Ltd. (CYTO) è $1.13M

Altamira Therapeutics Ltd. (CYTO) Rendimento del Dividendo

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

Anno	Rendimento da dividendi	Cambia
Non abbastanza dati per le date fornite.

Anno

Rendimento da dividendi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rendimento da dividendi	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.65%	BE

Azienda

Rendimento da dividendi

Il paese